Fig. 5

Extracellular LDLc decreases efficacy of sorafenib. HepG2 and HuH-7 cells were seeded. After adherence, they were pretreated with LDLc (100 μg/ml) in 5% LPDS for 24 h, followed by 5 μM of sorafenib (SORA) treatment for the next 48 h in the presence or absence of LDLc as indicated and processed as follows: a Cell images were taken by Olympus (DP-71) camera (magnification × 20). b Percentage of cell survival was determined using MTT assay. Vehicle-treated cells served as control and OD values of control were considered as 100% viable. Error bars represent variations within the wells of an experiment. c Long-term cell survival assay. d Whole cell lysates were resolved on SDS-PAGE, subjected to immunoblot analysis and expression of procaspase-3, cleaved PARP; PCNA were analyzed. β-Actin was used as loading control. Bar graph represents means ± standard deviation; **p < 0.01, ***p < 0.001 denotes significant differences between the groups